Notas de prensa

Papua New Guinea Hospital Selects Varian Cancer Care Solution

Varian (NYSE: VAR) today announced it was selected by Port Moresby General Hospital (PMGH) in Papua New Guinea to equip its cancer treatment center with the Halcyon™ radiotherapy system, as well...

Varian Acquires CyberHeart

Acquisition Key Highlights The CyberHeart acquisition secures significant intellectual property/patents that cover the use of radiation in the heart. Early positive clinical evidence suggests that...

Varian Selected to Equip Two Proton Therapy Centers in Norway

Following a comprehensive evaluation by Sykehusbygg HF Norway and regional health authorities, Varian (NYSE: VAR) was selected to equip two proton therapy centers in Norway with the ProBeam®...

Varian and Shandong Cancer Hospital Form Proton Therapy Clinical Application and Research Partnership in China

Varian (NYSE: VAR) today announced it has signed a strategic cooperation framework agreement with Shandong Cancer Hospital in China, for proton therapy clinical application and research. The...

Varian to Attend Upcoming Investor Events

Varian (NYSE: VAR) today announced that it will be attending the UBS Global Healthcare Conference (May 20-22) and the 2019 RBC Capital Markets Healthcare Conference (May 21-22) in New York City....

South Africa Hospital Delivers HDR Brachytherapy Cancer Treatments with Varian Bravos Afterloader System

Varian (NYSE: VAR) announced Groote Schuur Hospital in Cape Town, South Africa is the first hospital in Africa to deliver High Dose Rate (HDR) brachytherapy treatments with the Bravos™...

Ofuna Chuo Hospital Delivers First Varian Halcyon System Treatments in Japan

Varian (NYSE: VAR) today announced Ofuna Chuo Hospital, Kamakura City, Kanagawa Prefecture, Japan is the first clinic in the country to begin treating cancer patients using the Halcyon™...

Varian Announces Global Clinical Consortium to Develop Evidence-based Protocols for Adaptive Radiotherapy

Bringing together a global community of clinicians and scientists from leading cancer clinics to develop best practices for adaptive radiotherapy based on clinical evidence, Varian (NYSE: VAR)...

Varian Reports Results for Second Quarter of Fiscal Year 2019

Second Quarter 2019 Summary – Oncology gross orders grew 15% in dollars, or 18% in constant currency – Total company revenues grew 7% in dollars, or 10% in constant currency, to $779 million...

First Varian Halcyon Treatments in Kenya Begin at Nairobi West Hospital

Varian (NYSE: VAR) today announced that The Nairobi West Hospital in Nairobi, Kenya is the first clinic in the country and in West, Central, and East Africa to begin treating cancer patients using...